We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS.
- Authors
Messmer, M.; Stack, A.; Deng, M.; Handorf, E.; Kapoor, N.; Sawalha, Y.; Bock, A. M.; Wang, Y.; Graf, K.; Greenwell, B.; Cleveland, J.; Advani, R.; Herrera, D. Adrianzen; Cai, E.; Spinner, M.; Hassan, A.; Rajguru, S.; Phillips, M. S.; Smith, S. D.; Brooks, T.
- Abstract
For outcomes after auto-HCT, allogeneic transplant (allo-HCT), and chimeric antigen receptor T cell therapy (CAR-T), I TP53 i alteration must have been present at time of this therapy. Event free survival (EFS) after auto-HCT, allo-HCT, and CAR-T was defined as time from treatment to relapse, subsequent therapy, or death. OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI-INSTITUTION RETROSPECTIVE ANALYSIS.
- Subjects
CHIMERIC antigen receptors; MANTLE cell lymphoma; AUTOGRAFTS; CD19 antigen; BRUTON tyrosine kinase; TRANSPLANTATION of organs, tissues, etc.; MOTION sickness
- Publication
Hematological Oncology, 2023, Vol 41, p156
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_103